Celldex Therapeutics Inc
CLDX
View Detailed Chart
25.150USD
+0.690+2.82%
Market hours （ET）Quotes delayed by 15 min
1.67BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.82%
5 Days
+0.76%
1 Month
-1.37%
6 Months
+23.59%
Year to Date
-0.47%
1 Year
-39.02%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Buy
Current Rating
56.250
Target Price
+128.84%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 197.84% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.02M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 40.54.
Undervalued
The company’s latest PE is -8.11, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 75.86M shares, decreasing 15.48% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.94M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.51.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Ticker SymbolCLDX
CompanyCelldex Therapeutics Inc
CEOMr. Anthony S. Marucci
Websitehttps://celldex.com/
Related Instruments
-0.51%
-4.85%
+2.23%
+0.89%
-0.19%
+0.73%
+1.15%
+0.83%
+3.10%
+0.82%
-0.51%
-0.79%
+1.00%
+1.03%
+0.41%
+1.60%
+2.96%
0.00%
+1.67%
+2.93%
